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Introduction: This study is to evaluate whether thymidylate syn-
thase (TS) or thyroid transcription factor 1 (TTF1) protein expres-
sion can predict clinical outcomes for pemetrexed-based chemother-
apy in patients with nonsquamous non-small cell lung cancer
(NSCLC).
Methods: Two hundred eighty-five consecutive patients with nons-
quamous NSCLC treated with pemetrexed-based chemotherapy
were immunohistochemically analyzed for the expressions of TS
and TTF1.
Results: TS and TTF1 expression were successfully analyzed in 193
and 284 cases, respectively. Tumors with TS-negativity or TTF1-
positivity were more frequent in patients who were female, younger,
had adenocarcinoma, or had never smoked. Higher response rates
for pemetrexed-based chemotherapy were associated with TS-neg-
ativity (33.7% versus 14.1%, p  0.002) and TTF1-positivity
(28.1% versus 9.8%, p 0.001). In univariate analysis, progression-
free survival for pemetrexed-based chemotherapy was significantly
longer in groups with adenocarcinoma (2.9 versus 1.4 months, p 
0.001), TS-negativity (4.1 versus 2.0 months, p  0.001), and
TTF1-positivity (3.8 versus 1.3 months, p  0.001). In multivariate
analysis, TS-negativity (hazard ratio [HR]  0.70; 95% confidence
interval [CI], 0.51–0.97) and TTF1-positivity (HR  0.51; 95% CI,
0.35–0.73) were associated with longer progression-free survival.
Patients with TTF1-positive tumors also had significantly longer
overall survival times than patients with TTF1-negative tumors
(25.4 versus 14.2 months, HR  0.55; 95% CI, 0.39–0.77).
Conclusions: Low TS or high TTF1 protein expression was signif-
icantly associated with better clinical outcomes in nonsquamous
NSCLC patients who were treated with pemetrexed-based chemo-
therapy. The predictive role of TS or TTF1 expression should be
further validated in a prospective randomized study.
Key Words: Pemetrexed, Predictive factor, Thymidylate synthase,
Thyroid transcription factor 1, Non-small cell lung cancer.
(J Thorac Oncol. 2011;6: 1392–1399)
Pemetrexed, a multitargeted antifolate, is increasing itstherapeutic scope from second-line therapy to first-line
and maintenance therapy in the management of advanced
non-small cell lung cancer (NSCLC).1–3 Interestingly, two
phase III trials demonstrated that pemetrexed-based chemo-
therapy has a superior efficacy in patients with pulmonary
nonsquamous cell carcinoma compared with those with squa-
mous cell carcinoma.1,2 However, the reason for the variabil-
ity of pemetrexed activity according to different histotypes
has not been fully evaluated. In the same context, few
predictive molecular markers have been investigated in pem-
etrexed therapy for NSCLC. Therefore, additional predictive
markers for pemetrexed therapy, other than histotype, are
needed to select the patients who will benefit most from
pemetrexed therapy.
Thymidylate synthase (TS) is an important enzyme to
maintain DNA replication and repair mechanisms, and it is
also the main target of pemetrexed. The fact that TS expres-
sion level is higher in squamous cell carcinoma than in
nonsquamous cell carcinoma is the most probable theoretical
basis of the histotype-associated pemetrexed activity in
NSCLC.4 An in vitro study also recently suggested that the
mechanism of resistance to pemetrexed could be associated with
high TS levels in NSCLC.5 However, to date, there has been no
clinical study to demonstrate the relationship between pem-
etrexed efficacy and the level of TS expression in NSCLC.
Thyroid transcription factor 1 (TTF1) is a tissue-spe-
cific transcription factor expressed mainly in the epithelial
cells of the lungs and thyroid. TTF1 could be another poten-
tial molecular marker to explain the histotype-associated
pemetrexed activity, because pulmonary squamous cell car-
cinoma is known to express TTF1 less frequently than pul-
monary nonsquamous cell carcinoma.6,7
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Based on this, the aim of this study is to evaluate
whether TS or TTF1 protein expression can be a predictive
marker for the outcomes of pemetrexed-based chemotherapy
in patients with nonsquamous NSCLC.
MATERIALS AND METHODS
Study Sample
The study population consisted of 285 consecutive
patients who were treated with pemetrexed-based chemo-
therapy at Samsung Medical Center (Seoul, Korea) from
January 2007 to June 2010 and had simultaneously col-
lected specimens available for the immunohistochemical
analysis of TS or TTF1 protein expression. Clinicopatho-
logical data and follow-up information through December
24, 2010, were retrieved from medical records and are
summarized in Table 1. All patients had cytologically or
histologically confirmed nonsquamous NSCLC; histologic
types included adenocarcinoma (n  255), large cell carci-
noma (n  11), NSCLC-not otherwise specified (NSCLC-
NOS) (n  18), and pleomorphic carcinoma (n  1). Other
clinical characteristics such as performance status, age, and
stage were based on the data obtained when the advanced
stage lung cancer was diagnosed.
Of total 285 patients, 229 (80%) received pemetrexed
monotherapy and 56 (20%) received pemetrexed and platinum.
The first-line pemetrexed-based chemotherapy was given to 60
patients (21%), and other patients received pemetrexed as the
second-line (n 137, 48%) or later-line therapy (n 88, 31%).
In addition to pemetrexed-based chemotherapy, 182 patients
received at least one cycle of gemcitabine-based chemotherapy
(gemcitabine plus platinum: n 174, gemcitabine alone: n 8),
66 received taxane-based regimens (taxane plus platinum: n 
37, taxane alone: n  29), and 167 patients were treated with
epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itors (TKIs) (erlotinib: n  91, gefitinib: n  76) during the
follow-up period.
TABLE 1. Patient Characteristics and Univariate and Multivariate Analyses for Progression-Free
Survival (PFS) for Pemetrexed-Based Chemotherapy
No. of
Patients %
Median
PFS (mo)
Univariate
Analysis
p
Multivariate Analysis
HR 95% CI
All 285 100 2.7
TS expression 193 68 0.001
Negative 101 35 4.1 0.70 0.51–0.97
Positive 92 32 2.0
TTF1 expression 284 100 0.001
Positive 194 68 3.8 0.51 0.35–0.73
Negative 90 32 1.3
Gender 0.32 NA
Female 105 37 2.8
Male 180 63 2.6
Stage
IIIb 19 7 2.1 0.78 NA
IV 266 93 2.8
Age at diagnosis 0.79 NA
70 yr 36 13 2.5
70 yr 249 87 2.8
Histology 0.004a/0.001b
Adenocarcinoma 255 89 2.9 0.71a/0.72b 0.41–1.22a/0.42–1.23b
Nonadenocarcinoma (30) (11) (1.4)
Large cell carcinomac 11 4 1.4
NSCLC-NOS 18 6 1.8
Pleomorphic carcinoma 1 0 1.2
Smoking 0.10
Never-smoker 125 44 3.1 0.98 0.71–1.37
Ever-smoker 160 56 2.6
EGFR mutation 156 55 0.61 NA
Positive 53 19 3.7
Negative 103 36 3.1
a Values when analyzed among adenocarcinoma, large cell carcinoma, NSCLC-NOS, and pleomorphic carcinoma.
b Values when analyzed between adenocarcinoma and nonadenocarcinoma.
c Including eight cases of large cell neuroendocrine carcinoma.
NSCLC-NOS, non-small cell lung cancer-not otherwise specified; EGFR, epidermal growth factor receptor.
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Immunohistochemical Analyses for TS and
TTF1 Expression
All specimens used in this study were 4-m-thick
sections of paraffin-embedded tissue. Antigen retrieval con-
sisted of microwave heating (three cycles of 5 minutes at 700W)
in 10 mM citrate buffer at pH 6.0 and cooling to room
temperature for 20 minutes. After being washed in distilled
water, the slides were preincubated in 4% BSA and dextran
solution for 30 minutes to reduce nonspecific binding. The
slides were then incubated for 1 hours in a humidified
chamber at room temperature with monoclonal anti-TS
(4H4B1, Invitrogen, Carlsbad, CA) at a 1:200 dilution or
monoclonal anti-TTF1 (8G7G3/1, Dako, Carpinteria, CA) at
a 1:100 dilution, respectively. After being washed, the slides
were observed with peroxidase-labeled polymer conjugated
to goat anti-mouse immunoglobulins in Tris-HCl buffer and
incubated for 30 minutes at room temperature. The slides
were then washed and the chromogen was developed for 5
minutes with liquid 3,30-diaminobenzidine. Finally, tissue
sections were counterstained with hematoxylin, dehydrated,
and mounted in resinous mountant.
TS and TTF1 immunohistochemical staining was as-
sessed by two investigators (J.H. and J.S.) who reviewed the
cases simultaneously at a multihead viewing microscope,
without clinical information. In the evaluation of TS and
TTF1 expression, the immunostained cells were regarded as
positive when cytoplasmic or nuclear staining was identified.
The staining intensity within the tumor tissue was graded
on a scale of 0 (negative), 1 (low), and 2 (high). The
percentage of positive tumor cells was calculated for each
specimen. Then, this percentage was multiplied by the
staining intensity to obtain a final semiquantitative H-score
(possible range, 0 –200).
Statistical Analysis
Progression-free survival (PFS) was defined as the time
from the starting day of pemetrexed-based chemotherapy to
documented disease progression or death from any cause. For
patients without progressive disease at the time of analysis,
the patient was censored at the time of the last follow-up.
Overall survival was defined as the time from diagnosis to
death or to the date of the last follow-up.
The independent-samples t test was used to test signif-
icant associations between the TS H-score and histotypes.
The relationship between TS or TTF1 expression status
and clinicopathological factors or the response rates for
pemetrexed-based chemotherapy were analyzed using 2
tests. Survival curves were generated using the Kaplan-
Meier method, and the log-rank test was used to compare
survival curves according to clinicopathological character-
istics including TS and TTF1 status. A multivariate regres-
sion analysis was carried out using Cox’s regression anal-
ysis. All variables with a p value less than 0.10 at the time
of univariate analysis were entered into the multivariate
analysis model. p values less than 0.05 were considered
significant.
RESULTS
TS and TTF1 Protein Expression
Immunohistochemical analyses of TS and TTF1 were
successfully performed in 193 cases (TS cohort) and 284
cases (TTF1 cohort), respectively, because the others (92
cases and 1 case in the respective cohorts) lacked samples for
immunohistochemical analyses. The staining for TS appeared
in the nuclei and cytoplasm, while TTF1 staining was evident
predominantly in the nuclei of tumor cells (Figure 1). The
H-scores for TS (range, 1–120) and TTF1 (range, 0–200)
were analyzed. TS-positive tumors were defined as those with
an H-score higher than the median of 15. On the other hand,
the distribution of H-scores for TTF1 was easily divided into
two separate groups at an H-score of 10, and subsequently
tumors with H-scores for TTF1 of more than 10 were re-
garded as TTF1-positive. Among all evaluated patients, TS-
FIGURE 1. Immunohistochemical staining for thymidylate
synthase (TS) and thyroid transcription factor 1 (TTF1): TS
staining (A) was seen in both the nuclei and cytoplasm,
while TTF1 staining (B) was localized in the nuclei of tumor
cells.
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and TTF1-positive rates were 48% (92 of 193 evaluated
cases) and 68% (194 of 284 evaluated cases), respectively.
TS-negativity or TTF1-positivity was more frequently
shown in patients who were female, younger, had adenocar-
cinoma, or had never smoked (Table 2). When TS H-scores
among different histotypes (adenocarcinoma, NOS, and large
cell carcinoma) were compared, the level of TS expression
was significantly associated with the histotypes; adenocarci-
noma had the lowest TS level, followed by NOS and large
cell carcinoma in increasing order (Figure 2).
Association of TS and TTF1 Expression with
Outcome of Pemetrexed-Based Chemotherapy
The objective response rates of pemetrexed-based chemo-
therapy were 22.1% (63/285) for the entire group and 18.3%
(42/229) and 37.5% (21/56) for pemetrexed monotherapy and
pemetrexed plus platinum chemotherapy, respectively.
In the TS and TTF1 cohorts, the response rates for
pemetrexed-based chemotherapy were 24.7% (47/193) and
22.2% (63/284), respectively. Significantly higher response
rates were associated with TS-negativity compared with TS-
positivity (33.7% versus 14.1%, p  0.002), while patients
with TTF1-positive tumors achieved higher response rates
than those with TTF1-negative tumors (28.1% versus 9.8%,
p  0.001). In the evaluation of patients treated with pem-
etrexed monotherapy (149 and 228 cases in the TS and TTF1
cohorts, respectively), TS-negativity (28.4% versus 12.0%,
p  0.013) and TTF1-positivity (24.2% versus 6.7%, p 
0.001) were also associated with higher response rates. Sim-
ilarly, in the analysis of patients treated with pemetrexed plus
platinum therapy (44 and 56 cases in the TS and TTF1
cohorts, respectively), TS-negativity (48.1% versus 23.5%,
p 0.10) or TTF1-positivity (43.6% versus 23.5%, p 0.15)
tended to be associated with higher response rates.
The median PFS for pemetrexed-based chemotherapy
was 2.7 months (95% CI: 2.5–3.0 months) for all study
population. Clinical characteristics such as adenocarcinoma,
TS-negativity, and TTF1-positivity were significantly associ-
ated with longer PFS in univariate analyses (Table 1). Nota-
bly, the median PFS for pemetrexed-based chemotherapy was
significantly longer in the TS-negative group than in the
TS-positive group (4.1 versus 2.0 months, p  0.001, Figure
3A), and the median PFS in the TTF1-positive group was 3.8
FIGURE 2. Thymidylate synthase (TS) H-scores according
to histotype. Ad, adenocarcinoma; LCC, large cell carci-
noma.
TABLE 2. Positive Rates of Thymidylate Synthase (TS) and Thyroid Transcription Factor 1 (TTF1) According
to Clinicopathological Factors
TS (N  193) TTF1 (N  284)
All
(N)
Positive
(N)
Positive
Rates (%) p
All
(N)
Positive
(N)
Positive
Rates (%) p
All evaluable patients 193 92 48 284 194 68
Gender 0.005 0.007
Female 72 25 35 105 82 78
Male 121 67 55 179 112 63
Age at diagnosis 0.052 0.02
70 yr 26 17 65 35 18 51
70 yr 167 75 45 249 176 71
Histology 0.001 0.001
Adenocarcinoma 172 72 42 254 185 73
Large cell carcinoma 9 9 100 11 3 27
NSCLC-NOS 12 11 92 18 6 33
Pleomorphic carcinoma 1 0 0
Smoking 0.02 0.001
Never-smoker 86 33 38 125 100 80
Ever-smoker 107 59 55 159 94 59
NSCLC-NOS, non-small cell lung cancer-not otherwise specified.
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months compared with 1.3 months in the TTF1-negative
group (p  0.001, Figure 3B). Upon multivariate analysis,
only TS-negativity (HR  0.70, 95% CI: 0.51–0.97) and
TTF1-positivity (HR  0.51, 95% CI: 0.35–0.73) were
significantly associated with better clinical outcomes for
pemetrexed-based chemotherapy with regard to PFS. Further-
more, when the study sample was subdivided according to TS
and TTF1 expression into four subgroups (TS/TTF1,
TS/TTF1, TS/TTF1, and TS/TTF1), the PFS
curve of each subgroup was distinctly separate, with the
longest PFS for the TS/TTF1 group, followed in descend-
ing order by the TS/TTF1, TS/TTF1, and TS/
TTF1 groups (p  0.001, Figure 3C).
The median PFS for pemetrexed monotherapy was 2.5
months in both the TS (95% CI: 1.9–3.1 months) and TTF1
(95% CI: 2.1–2.9 months) cohorts. Tumors with TS-negativ-
ity (3.0 versus 2.0 months, p 0.016) or TTF1-positivity (3.0
versus 1.3 months, p  0.001) were significantly associated
with a longer PFS for pemetrexed monotherapy. For patients
treated with pemetrexed plus platinum, the medians for PFS
were 5.5 months (95% CI: 4.5–6.6 months) and 5.3 months
(95% CI: 4.2–6.5 months) in the TS and TTF1 cohorts,
respectively. Likewise, TS-negativity (6.0 versus 4.9 months,
p  0.08) and TTF1-positivity (6.0 versus 4.8 months, p 
0.12) were associated with a longer PFS for pemetrexed plus
platinum chemotherapy.
Association of TS and TTF1 Expression with
Overall Survival and Outcome for Other
Chemotherapeutic Regimens
The median overall survival time from the date of
diagnosis was 20.9 months (95% CI: 18.3–23.4 months) for
the entire cohort. Some characteristics such as being female
(25.5 versus 17.5 months, p 0.001), an Eastern Cooperative
FIGURE 3. Analyses of progression-free survival (PFS) according to thymidylate synthase (TS) protein expression (A), thyroid
transcription factor 1 (TTF1) protein expression (B), and the combination of TS and TTF1 protein expression (C).
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Oncology Group performance status of 0 or 1 (21.6 versus
17.7 months, p  0.001), an age younger than 70 years (22.3
versus 12.5 months, p  0.001), adenocarcinoma (21.7 ver-
sus 12.8 months, p  0.015), having never smoked (24.6
versus 17.5 months, p  0.002), and TTF1-positivity (25.4
versus 14.2 months, p  0.001) were determined to be
associated with longer overall survival in univariate anal-
yses. Patients with TS-negative tumors tended to live
longer than those with TS-positive tumors (22.3 versus
18.9 months, p  0.106). Upon multivariate analysis, TTF1-
positivity (HR  0.55; 95% CI: 0.39–0.77), good perfor-
mance status (HR  0.61; 95% CI: 0.41–0.90), and younger
age (HR  0.56; 95% CI: 0.36–0.86) were independent
factors affecting prolonged overall survival.
Because most of the patient population had received
more than two lines of chemotherapy, we also evaluated the
relationships of TS or TTF1 protein expression with clinical
outcomes for other chemotherapeutic regimens such as gem-
citabine-based, taxane-based, and EGFR TKI chemotherapy.
Clinicopathological characteristics such as gender, age, his-
tology, smoking status, TS expression, TTF1 expression, and
EGFR mutation status were also analyzed for possible pre-
dictive factors for these chemotherapeutic regimens. For
gemcitabine-based chemotherapy, only TTF1-positivity was
associated with the prolongation of PFS in univariate analysis
(5.1 versus 4.1 months, p  0.001). For EGFR TKI therapy,
TTF1-positivity (HR  0.48, 95% CI: 0.26–0.89) and acti-
vating EGFR mutation (HR  0.40, 95% CI: 0.24–0.67)
independently predicted better clinical outcomes. However,
there was no clinicopathological factor that could be used to
differentiate outcomes for taxane-based chemotherapy.
Association between EGFR Mutation and
Clinical Outcome After Pemetrexed-Based
Therapy
EGFR mutation was analyzed for 156 patients. Fifty-
three patients (34%) had positive activating EGFR mutation
tumors. There were no difference between EGFR-positive
and EGFR-negative groups in terms of PFS (3.7 versus 3.1
months, p  0.57) and OS (25.2 versus 22.7 months, p 
0.25) after pemetrexed-based therapy.
DISCUSSION
To our knowledge, this is the first report to evaluate the
predictive role of TS or TTF1 protein expression in a large
cohort of nonsquamous NSCLC patients treated with pem-
etrexed-based chemotherapy. According to these results, low
TS or high TTF1 expression could be predictive of higher
response rates and prolongation of PFS in nonsquamous
NSCLC patients treated with pemetrexed-based chemother-
apy. It is also of note that high TTF1 expression was signif-
icantly associated with longer overall survival and better
outcomes not only for pemetrexed-based chemotherapy but
also for gemcitabine-based chemotherapy and EGFR TKI
therapy.
It is usually difficult to differentiate the role of some
clinicopathological characteristics between predictive and
prognostic factors in advanced NSCLC, because the innate
prognostic properties influence the outcome for specific che-
motherapy and the efficacy of chemotherapy inversely can
affect overall survival. In this study, TTF1-positivity was
simultaneously associated with longer overall survival and
PFS for several chemotherapeutic drugs, although not for
taxane-based chemotherapy. Therefore, it is possible that the
innate good prognostic properties of TTF1 influenced the
efficacy data for several chemotherapeutic drugs. Even
though the prognostic role of TTF1 cannot be determined in
this study because patients who had not been exposed to
pemetrexed were not analyzed, our results suggest that TTF1
expression could provide a good prognostic marker in
NSCLC, which is consistent with previous studies.6–14
A previous study with a relatively large cohort showed
that TTF1 expression impacted positively on the survival of
stage I pulmonary adenocarcinoma patients.14 A meta-analy-
sis also observed that high TTF1 protein expression is asso-
ciated with better survival in NSCLC, mainly in early-stage
NSCLC.12 These studies demonstrated that TTF1 can be a
prognostic factor in early-stage NSCLC because most pa-
tients did not receive any adjuvant therapy, and subsequently
survival was less likely to be affected by other treatments, as
compared with surgical resection. The prognostic role of
TTF1 even in advanced-stage NSCLC was previously eval-
uated in two small studies that suggested the good prognostic
value of TTF1 positivity.11,13 There are also a few preclinical
reports supporting the good prognostic value of TTF1 posi-
tivity in NSCLC. Saito et al.15 demonstrated that TTF1 can
exert a tumor-suppressive effect by inhibiting transforming
growth factor--mediated epithelial to mesenchymal transi-
tion, subsequently decreasing the invasive capacity of lung
cancer cell lines. In addition, when grouping pulmonary
adenocarcinoma according to gene expression profiles, TTF1
could be used as a marker to characterize distinct groups with
good prognoses.16 Therefore, we should be cautious in draw-
ing firm conclusions from this study that TTF1 expression is
a specific predictive factor for pemetrexed-based chemother-
apy in nonsquamous NSCLC.
In contrast, TS-negativity was associated with better
outcomes for only pemetrexed-based chemotherapy in this
study. Therefore, it is reasonable to consider TS expression as
a specific predictive factor for pemetrexed-based chemother-
apy. TS expression has been previously considered as a
potential predictive factor for pemetrexed therapy based on
several observations. Namely, the fact that TS is a main target
enzyme of pemetrexed, combined with the data that TS
expression is significantly higher in squamous cell carcinoma
than in nonsquamous cell carcinoma4 and that the efficacy of
pemetrexed-based chemotherapy has been poor for pulmo-
nary squamous cell carcinoma,3,17,18 suggests that TS gene or
protein levels may be a potential predictive factor for pem-
etrexed-based chemotherapy. In a phase II trial with breast
cancer, a low TS mRNA level tended to be associated with a
higher response to pemetrexed (p 0.103). Two independent
clinical studies also suggested that TS level could predict the
efficacy of 5-fluorouracil, another TS inhibitor, in colorectal
and neuroendocrine tumors.19,20 However, considering the
lack of previous clinical reports documenting the role of TS
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expression for pemetrexed-based chemotherapy in NSCLC,
this study would be a pivotal work that has demonstrated the
role of TS protein expression as a predictive marker in
nonsquamous NSCLC patients treated with pemetrexed.
It seems paradoxical that high intratumoral target en-
zyme (TS) expression is inversely related with the efficacy of
pemetrexed. Although the reason of this paradoxical situation
cannot be explained in this study, the inverse relationship
between TS expression and the efficacy of other TS-inhibitors
has been found in previous studies.21 In several preclinical
studies, the levels of TS activity increased after exposure to
5-fluorouracil and other TS-specific inhibitors.22 Moreover,
acute increases of TS protein levels was observed in paired
tumor tissues obtained from breast cancer patients before and
during therapy with 5-fluorouracil.23 The elevation of TS
expression was regarded as a mechanism by which cancers
developed acute resistance to 5-fluorouracil.
Given the heterogeneity of TS expression within indi-
vidual tumors,24,25 issues can be raised regarding the repre-
sentativeness of TS expression in small-volume samples of
the true TS expression status of tumors. However, a signifi-
cant concordance in TS protein expression was found be-
tween preoperatively acquired cytological specimens of
NSCLC and the corresponding samples acquired at the time
of subsequent surgical resection in a previous study.26 Actu-
ally, in this study, most samples had been acquired by
percutaneous needle biopsy or bronchoscopic biopsy, and the
TS expression analysis from these small-volume specimens
was found to be valuable to predict outcomes in NSCLC
patients treated with pemetrexed-based chemotherapy.
Another positive aspect of the evaluation of TS and
TTF1 expression is that the immunohistochemical analysis
can supplement the incomplete morphologic classification of
the histotypes in NSCLC. According to a previous study that
reviewed 100 consecutive lung cancer specimens, among 27
specimens previously diagnosed as squamous cell carcinoma,
an adenocarcinoma component was found in four cases
(15%).27 In the same context, the error rate can be consider-
able in the classification of histotypes according to morpho-
logic features from small specimens. A previous study
showed that 8 of 102 cases of squamous cell carcinoma
diagnosed from bronchoscopically biopsied specimens turned
out to be nonsquamous cell carcinomas (five adenocarcino-
mas and three large cell carcinomas) after surgical resec-
tion.28 As a result, pemetrexed therapy could be mistakenly
selected if it were performed based solely on the morpholog-
ically classified histotype. Therefore, the prior evaluation of
TS and TTF1 could compensate for the possible error in the
decision of pemetrexed therapy for NSCLC.
Regarding the methodology of TS measurement in
tumor tissue, quantitative real-time reverse transcription-
polymerase chain reaction (RT-PCR) has been used to detect
TS expression at the mRNA level, which is highly sensitive
and semiquantitative. However, considering the poor acces-
sibility of adequate amounts of fresh tumor samples in ad-
vanced-stage NSCLC and the cost of RT-PCR, immunohis-
tochemical analysis would be more popular and feasible in
clinical practice. In addition, it has been reported that there is
a strong correlation between TS protein and mRNA lev-
els.4,20,26,29 Therefore, this study raises the possibility that
immunohistochemical analysis for TS may be a useful
method to select patients with advanced NSCLC for pem-
etrexed-based chemotherapy.
Despite the retrospective nature of this study and the
fact that the data were drawn from a single institute, this is the
first report to document the significance of TS and TTF1
protein expression in a large number of NSCLC patients
treated with pemetrexed. In addition, a broad range of data
from overall survival to the efficacy of other chemotherapeu-
tic agents were thoroughly analyzed according to several
clinicopathological factors, including TS and TTF1 expres-
sion, to detect the specific predictive factors for the outcome
of pemetrexed-based chemotherapy.
In conclusion, in patients with advanced nonsquamous
NSCLC treated with pemetrexed-based chemotherapy, low
TS or high TTF1 protein expression was significantly asso-
ciated with better clinical outcomes for the pemetrexed-based
chemotherapy. Therefore, TS or TTF1 protein expression in
tumor tissue might be a useful predictive marker for the
selection of patients for pemetrexed-based chemotherapy in
clinical practice. However, in the case of TTF1 expression, it
may be appropriate to consider its prognostic properties as
well as its predictive role for pemetrexed-based chemother-
apy in nonsquamous NSCLC, based on the present relation-
ship of TTF1 expression with a broad range of clinical
outcomes, including overall survival and the efficacy of
several other chemotherapeutic regimens. Furthermore, the
predictive roles of TS and TTF1 expression for pemetrexed-
based therapy should be validated in a prospective and
randomized study.
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